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Does Intravenous Infusion Influence
Diagnostic Ultrasound-Induced
Pulmonary Capillary Hemorrhage?
Douglas L. Miller, PhD , Zhihong Dong, MD, Chunyan Dou, MD, Krishnan Raghavendran, MD
Objectives—Pulmonary diagnostic ultrasound (US) can induce pulmonary capillary
hemorrhage (PCH) in mammals. This singular biological effect of diagnostic US
imaging was discovered more than 25 years ago but remains poorly understood.
Our objective here was to investigate rapid infusion of intravenous fluids as a possi-
ble stressor for capillaries, which might enhance pulmonary diagnostic US-induced
PCH.
Methods—Rats were anesthetized with Telazol (Zoetis, Inc, Kalamazoo, MI),
which yielded relatively low pulmonary diagnostic US-induced PCH, or Telazol and
xylazine, which yielded relatively high pulmonary diagnostic US-induced PCH.
Groups of rats were not infused or infused either with normal saline, 10% mannitol,
or 5% albumin. Rats were scanned in a warmed water bath with B-mode US for 5
minutes with a 7.6-MHz linear array set to different mechanical index values to
obtain exposure response information. Pulmonary capillary hemorrhage was
observed as comet tail artifacts in the image and measured on the lung surface.
Results—For Telazol anesthesia, all of the PCH results were very low, with no sig-
nificant differences at the maximum output with an in situ peak rarefactional pres-
sure amplitude of 2.1 MPa (on-screen mechanical index, 0.9). The addition of
xylazine to the Telazol anesthetic significantly enhanced the PCH (P< .001) with-
out infusion and likewise for the mannitol and albumin infusion. Saline infusion
eliminated this enhancement, with significantly reduced PCH for Telazol-plus-
xylazine anesthesia (P< .001); however, both mannitol and albumin infusion
resulted in significantly more PCH than saline infusion (P< .01).
Conclusions—These results show PCH dependence on the specific intravenous
infusion fluid and illustrate the complex importance of physiologic parameters for
US-induced PCH.
Key Words—animal studies; basic science (bioeffects); chest/lung; comet tail
artifact; crystalloid and colloid infusion; diagnostic ultrasound safety;
emergency medicine; mechanical index; pulmonary ultrasound; ultrasound
techniques/physics
D iagnostic ultrasound (US) imaging of mammalian lung caninduce pulmonary capillary hemorrhage (PCH). The induc-tion of PCH by pulsed US was discovered more than 25
years ago1 but remains poorly understood. Reviews of research have
indicated that the phenomenon occurs in mice, rats, and pigs and
may be characterized by a threshold for a specific situation.2,3 Initially,
the lung was expected to receive mostly incidental exposure, such as
during echocardiography; therefore, no specific guidance was devised
for avoidance of the effect.3 At this time, however, direct pulmonary
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diagnostic US has become routine in intensive care,
emergency care, and point-of-care medical settings.4–7
Pulmonary diagnostic US has been found to be valuable
in diagnosis of pneumonia, pulmonary edema, embo-
lism, pneumothorax, atelectasis, diffuse parenchymal dis-
ease, respiratory distress syndrome, and lung cancer.8
The use of portable US machines allows pulmonary
diagnostic US examinations to be performed by the phy-
sician at the bedside, essentially replacing the stetho-
scope.9–11 This rapidly expanding use of pulmonary
diagnostic US lends some urgency to efforts to define
the possible risks of PCH for patients and to provide
suitable safety guidance.
Our research has used actual diagnostic US systems
(early work used single-element laboratory systems) to
provide relevant information, including pulmonary diag-
nostic US images, which display the occurrence of PCH
as comet tail artifacts extending from the pleura toward
the interior.12 The thresholds for this bioeffect appear to
have little frequency dependence,13 which suggests that
the mechanism of acoustic radiation pressure may play a
role in the induction of PCH.14 Pulmonary capillary
hemorrhage has a strong dependence on poorly defined
physiologic conditions: the anesthesia methods, such as
the use of xylazine, are very important for pulmonary
diagnostic US-induced PCH in rats.15 The enhancement
phenomenon also occurs for dexmedetomidine, a com-
mon clinical sedative that causes little or no respiratory
depression.16 These findings imply that many patient
medical treatments could influence pulmonary diagnos-
tic US-induced PCH in uncertain ways. Some patient
conditions or treatments may worsen the risk, whereas
others may alleviate the risk.
The finding that the PCH effect is low for ketamine
and higher for ketamine-plus-xylazine anesthesia15 pro-
vided a means to test drug treatments and other physio-
logic conditions for their influence on the bioeffect. For
ketamine, conditions leading to enhanced PCH may be
more evident than for ketamine plus xylazine, which
already enhances the PCH. Conversely, conditions lead-
ing to reduced PCH may be more evident for ketamine
plus xylazine than for ketamine anesthesia, which already
has a low effect. Therefore, testing rat models of various
clinical conditions with both ketamine and ketamine-
plus-xylazine anesthesia could readily identify conditions
that either enhance or reduce PCH. One problem with
this duel strategy is that ketamine, a dissociative agent,17
provides poor muscle tone, immobility, and analgesia at
normal doses. Telazol (Zoetis, Inc, Kalamazoo, MI),
which consists of tiletamine (related to ketamine) plus
zolazepam (benzodiazepine-related tranquilizer), is an
attractive alternative to ketamine and provides light anes-
thesia with immobility. In this study, Telazol was com-
pared to Telazol plus xylazine for use as a dual strategy
of evaluating physiologic conditions for their influence
on pulmonary diagnostic US-induced PCH.
A conceptually simple physiologic condition is the
infusion of intravenous (IV) fluids. Rapid infusion of IV
fluids, such as saline, can lead to hypervolemia and even-
tual pulmonary edema, which is identifiable by diagnos-
tic US B-lines.18 Hypothetically, fluid infusion leading to
vascular hypervolemia and possibly to pulmonary edema
may do so by stressing pulmonary capillaries, thus pre-
disposing the lung to PCH. Saline is a crystalloid infu-
sion fluid that rapidly distributes between vascular and
tissue interstitial compartments. Another clinical IV fluid
is mannitol, a sugar alcohol used at a hypertonic concen-
tration to dehydrate tissues, such as to reduce intracra-
nial pressure due to severe traumatic brain injury owing
to its inability to cross the blood-brain barrier. Mannitol
also can cause diuresis, possibly reducing edema, such as
pulmonary edema.19 Clinical IV infusion of an albumin
solution can produce increased pulmonary blood vol-
ume without potentially increasing pulmonary edema.18
Intravenous albumin is a colloid fluid that tends to
remain within the vasculature, thus increasing plasma
volume. Rapid infusion of very high volumes (eg, 10%
of body weight) of saline, mannitol, or plasma, can lead
to a life-threatening fluid overload, which tends to pro-
duce pulmonary interstitial edema with saline, alveolar
edema with plasma (albumin), and both with hypertonic
mannitol.20 In this study, pulmonary diagnostic US-
induced PCH variations from infusion of these fluids
were assessed by using the strategy of Telazol in com-
parison to Telazol-plus-xylazine anesthesia.
Materials and Methods
Animal Preparation
All in vivo animal procedures were conducted with the
approval and guidance of the Institutional Animal Care
and Use Committee of the University of Michigan.
Female rats (Sprague Dawley; Charles River, Wilming-
ton, MA) were used for this study, as described previ-
ously.12 Anesthesia was accomplished either with
Telazol at 90 mg/kg only or with Telazol plus xylazine
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(Xylamed injection; Bimeda-MTC Animal Health, Inc,
Cambridge, Ontario, Canada) at 9 mg/kg. The use of
xylazine for anesthesia was previously shown to enhance
pulmonary diagnostic US-induced PCH,15 possibly due
to an impact on pulmonary capillaries. The use of high
doses of xylazine is also associated with induction of pul-
monary edema.21,22 The right thorax of all rats was
shaved and depilated for US transmission. The rats were
mounted in a 38 8C degassed water bath for US expo-
sures of the right lung. This water bath method provides
reproducible US coupling and exposure and maintains
the body temperature of the rats.
A jugular vein catheter was set for IV injection of
fluids in the second part of the study. Three IV fluids
were used: normal saline (0.9% sodium chloride injec-
tion; Hospira, Lake Forest, IL) was the standard medical
IV solution administered for fluid replenishment. Manni-
tol, 10% (Osmitrol 10% mannitol injection; Baxter
Healthcare, Deerfield, IL), was a hypertonic diuretic that
acted to dehydrate tissue with 596 mOsmol. Albumin
(albumin 5% solution; CSL Behring, LLC, Kankakee,
IL) was given as a volume-expanding colloid with nor-
mal osmolarity (310 mOsmol). These fluids were
injected rapidly via a syringe pump at 7 ml/kg/min for 5
minutes just before US scanning, which was intended to
perturb the pulmonary capillaries in these acute tests.
The rats were then scanned by diagnostic US for 5
minutes, followed by euthanasia 5 minutes later. This
infusion volume totaled 3.5% of body weight (50% of
blood volume). This level of infusion did not produce
discernable stress in the rats over the time of the tests,
which can occur for higher infusion volumes. In an acute
study by Manenti et al,20 infusion of 10% of body weight
of these IV fluids resulted in tachypnea and cyanosis, fol-
lowed by death within 15 minutes.
Ultrasound
An HDI 5000 diagnostic US machine (Philips Health-
care, Andover, MA) with a CL15-7 linear array was used
for B-mode scanning with a 2-cm image depth, a 1-cm
focal depth, and 39 frames per second, as described pre-
viously.12 The transducer was set up in the water bath
with an adjustable gantry to aim through an intercostal
space at the right cranial or medial lobe of the rat lung.
The pleural surface was at a depth of about 5 to 6 mm,
with the transducer partially in contact with the skin.
The pulses of US had a center frequency of 7.6 MHz
with a pulse repetition frequency of 10 kHz. The on-
screen mechanical index (MI) was set to 0.21 for aiming
and then quickly raised to an on-screen MI of 0.37, 0.52,
0.7, or 0.9 (maximum for this transducer) for 5 minutes
of scanning. The acoustic parameters were measured
with a calibrated hydrophone as described previously13
and are listed in Table 1, including peak rarefactional
pressure amplitude, peak mean pressure amplitude, and
spatial-peak pulse-average intensity.
Measured End Points
Measured physiologic parameters included heart rate
and oxygen saturation (Physiosuite; Kent Scientific
Corp, Torrington, CT). This system allowed measure-
ment of higher heart rates than possible with standard
veterinary monitors. The wet/dry weight of the left lobe
of the lung was measured by weighing the sample, dry-
ing for 24 hours at 37 8C, and reweighing. For the rats
with infusion, the hematocrit was measured in baseline
samples and in posttest samples. This information was
used to estimate the percentage of increase in blood vol-
ume accomplished by the infusions as 100 times the dif-
ference between the posttest hematocrit and baseline,
divided by the baseline result. In addition, a noninvasive
blood pressure system (Coda monitor; Kent Scientific
Corp) was used on the tail of the rats to measure blood
pressure before and after the test.
Exposure-related end points included the percent-
age of the bright-line image of the lung surface, which
was involved with comet tail artifacts at the end of
exposure, and measurement of PCH areas on the lung
surface, as described previously.12,13,15,16 Briefly, at
euthanasia, the trachea was tied off, and the lungs were
removed. The right lobes, which were the targets of the
imaging, were then examined and photographed by a
stereomicroscope with a digital camera (Spot Flex; Diag-
nostic Instruments, Inc, Sterling Heights, MI). The
Table 1. Measured In Situ Exposure Parameters for the
On-screen MI settings Used Here
On-screen PRPA, PMPA, ISPPA,
MI MPa MPa W cm22
0.9 2.13 6 0.21 2.77 6 0.18 170 6 20
0.7 1.71 6 0.19 2.22 6 0.16 114 6 15
0.52 1.34 6 0.13 1.68 6 0.14 75 6 13
0.37 1.02 6 0.11 1.22 6 0.11 40.5 6 7.4
0.21 (aiming) 0.55 6 0.06 0.62 6 0.06 10.4 6 2.0
Data are presented as mean 6 SD. ISPPA indicates spatial-peak
pulse-average intensity; PMPA, peak mean pressure amplitude;
and PRPA, peak rarefactional pressure amplitude.
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photographs of the lungs were used to measure the
approximate diameter and area of the region of PCH
on the lung surface with image analysis software (Spot
version 5.1; Diagnostic Instruments, Inc). The PCH
was readily identified as irregular bright red areas along
the line of the US scan plane and often the same length
as the comet tail artifact length in the image. These
were manually outlined by the software with the appro-
priate scale calibration, which gave the area in square
millimeters.
Experimental Plan and Statistics
The comparison of Telazol-only to Telazol-plus-xylazine
(TX) anesthesia was performed first, and the results
indicated that the different anesthetics provided a rea-
sonable dual-test strategy. This finding led to perform-
ance of the experiments with Telazol only and Telazol
plus xylazine for each infusion solution. The two parts
were done by the same methods, except for the added
hematocrit and blood pressure measurements for the
infusion part. Physiologic parameters for the experimen-
tal conditions are listed in Table 2. The addition of xyla-
zine for Telazol-plus-xylazine anesthesia gave significant
reductions in the heart rate, oxygen saturation, and
blood pressure relative to Telazol only, as expected. For
each condition, groups of 5 or 6 rats were scanned at the
maximum on-screen MI value of 0.9 and additional
lower values including on-screen MIs of 0.7, 0.52,
and 0.37. For reference, the guideline upper limit for
diagnostic US is an on-screen MI of 1.9, which is sub-
stantially higher than available from the small, high-
resolution transducer. The response for Telazol-only
conditions was very low for the infusion tests, and only
on-screen MI 0.9 groups were included. One sham
Telazol-plus-xylazine group was included, using the on-
screen MI for aiming only. A total of 42 rats (7 groups
of 6) were included in the Telazol-only versus Telazol-
plus-xylazine test, and 65 rats were included in the infu-
sion experiment (13 groups of 5). The groups and expo-
sure parameters are presented in Table 3. Statistical
comparisons used the z test of proportions for compari-
son of two groups, with significance assumed at
P .053 (P 5 .053 corresponds to 4/5 positive results,
compared to 0/5 for shams). The results were unexpect-
edly mostly negative. Therefore, the lowest on-screen
MI group for each Telazol-plus-xylazine condition,
which was extended to lower values until no positive
effect was found, was considered a sham. Two-way anal-
yses of variance were conducted to compare the impor-
tance of the on-screen MI exposure setting relative to
the addition of xylazine (Telazol only versus Telazol
plus xylazine) and relative to the infusion solutions
(saline, mannitol, and albumin). In addition, a linear
regression was performed on the exposure response
trends of groups including any PCH detected to esti-
mate thresholds as the 0-crossing point.
Results
The general physiologic measurements are listed in
Table 2. The differences in the heart rate, oxygen satura-
tion, and blood pressure were all highly significantly dif-
ferent (P< .01) between Telazol-only and Telazol-plus-
xylazine anesthesia. The mean blood pressure values
were variable for the noninvasive method, and there
were no significant differences between before and after
values. For Telazol wet/dry ratios, there was a significant
decrease for saline infusion, no significant difference for
mannitol infusion, but a significant increase for albumin
infusion. For Telazol plus xylazine, all of the wet/dry
Table 2. Measured Physiologic Parameters for the 4 Different Conditions With and Without Xylazine
Telazol Only Telazol 1 Xylazine
Parameter None Saline Mannitol Albumin None Saline Mannitol Albumin
n 18 5 5 5 24 10 20 20
Weight, g 255 6 9 261 6 19 257 6 25 262 6 26 251 6 16 268 6 18 253 6 16 258 6 24
HR, beats/min 437 6 58 415 6 36 410 6 48 420 6 28 249 6 27 295 6 39 316 6 49 322 6 39
SpO2, % 93 6 5 88 6 6 84 6 9 89 6 4 77 6 9 79 6 12 82 6 8 76 6 8
MBP before, mm Hg 126 6 28 115 6 19 113 6 18 82 6 20 78 6 14 94 6 28
MBP after, mm Hg 109 6 36 96 6 18 99 6 17 81 6 11 81 6 14 78 6 15
Wet/dry 4.3 6 0.2 4.1 6 0.1 4.5 6 0.6 4.9 6 0.3 4.2 6 0.2 4.5 6 0.3 4.5 6 0.3 4.8 6 0.4
BV increase, % 23 6 9 31 6 7 37 6 14 23 6 11 30 6 13 34 6 13
Data are presented as mean 6 SD where applicable. BV indicates blood volume; HR, heart rate; MBP, mean blood pressure before and
after infusion; and SpO2, oxygen saturation.
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results for the infusions were significantly greater than
for no infusion. The hematocrit of about 0.45 was
reduced for all 3 infusions by 18% to 27%, with a statisti-
cally significant blood volume increase for albumin infu-
sion relative to no infusion.
The measured end point results are presented in
Table 3. The primary measure of the effect was the
PCH area. The comet tail artifacts were also measured
and closely tracked the PCH length on the lungs. For
the comparison of Telazol-only and Telazol-plus-
xylazine anesthesia, the added xylazine yielded a signifi-
cant increase in PCH at the on-screen MI of 0.9
(P< .001), and greater observed PCH at lower on-
screen MI values. The analyses of variance showed that
the xylazine had a significant impact (P< .001) as did
the on-screen MI setting (P< .001); furthermore, the
on-screen MI of 0.9 was statistically significantly differ-
ent from on-screen MIs of 0.37, 0.52, and 0.7. This
observation was similar to ketamine compared to
ketamine-plus-xylazine results15 and indicated that the
strategy of Telazol-only versus Telazol-plus-xylazine tests
for gauging the influence of different conditions on
PCH sensitivity was plausible.
A comparison between the no-infusion and infusion
parts of the study revealed no substantial enhancement
due to the infusions, as shown in Figure 1 for the on-
screen MI 0.9 setting. All of the infusions for Telazol
only led to PCH, which was not significantly different
from 0, apparently reducing the significant PCH seen
for Telazol only without infusion. All of the PCH results
with Telazol plus xylazine were significantly greater
(P< .01) than the corresponding Telazol-only condi-
tion except for the saline infusion, which was somewhat
less (P 5 .078). However, the saline infusion with Tela-
zol plus xylazine produced a substantial reduction in
PCH relative to the Telazol plus xylazine without infu-
sion (P< .001).
For the infusion part of the study, no significant
PCH was observed for Telazol-only anesthesia (Figure 1).
For Telazol-plus-xylazine anesthesia, the PCH for man-
nitol or albumin infusion was comparable to the no-
infusion result (Figure 1). The PCH for saline infusion
Table 3. Pulmonary Capillary Hemorrhage Results for Diagnostic US Scanning at the Indicated Onscreen MIs
On-screen US CTA, CTA, Positive Area, Intercept,
Condition MI mm % Proportion mm2 MPa r2
TO, none 0.9 2.7 6 2.9 26 6 28 5/6 1.3 6 1.0a
TO, none 0.7 0.8 6 1.3 8.7 6 14.7 2/6 0.2 6 0.3 1.6 0.37
TO, none 0.52 0 0 0/6 0
TX, none 0.9 8.4 6 2.3 87 6 24 6/6 4.6 6 1.3a
TX, none 0.7 2.3 6 2.8 36 6 30 4/6 1.2 6 1.9
TX, none 0.52 0.4 6 0.7 4.3 6 6.8 2/6 0.08 6 0.14 1.4 0.67
TX, none 0.21 0 0 0/6 0
TO, saline 0.9 0.2 6 0.5 2.0 6 4.4 1/5 0.37 6 0.83 ND
TX, saline 0.9 1.7 6 1.9 19 6 21 3/5 0.5 6 0.6
TX, saline 0.7 0.2 6 0.5 2.4 6 5.3 1/5 0.01 6 0.03 1.7 0.33
TO, mannitol 0.9 0.4 6 0.8 3.0 6 6.7 1/5 0.8 6 1.8 ND
TX, mannitol 0.9 4.4 6 3.4 44 6 36 4/5 4.2 6 3.6a
TX, mannitol 0.7 4.5 6 2.3 46 6 23 5/5 2.6 6 2.2a
TX, mannitol 0.52 0.9 6 1.2 9.9 6 14.5 1/5 0.3 6 0.7 1.3 0.33
TX, mannitol 0.37 0 0 0/5 0
TO, albumin 0.9 0.4 6 1.0 3.8 6 4.5 1/5 2.1 6 4.6 ND
TX, albumin 0.9 5.8 6 3.1 57 6 28 5/5 7.3 6 4.7a
TX, albumin 0.7 2.5 6 3.4 25 6 31 3/5 3.1 6 4.0
TX, albumin 0.52 1.0 6 1.7 9.5 6 15.4 2/5 1.3 6 2.1 1.2 0.45
TX, albumin 0.37 0 0 0/5 0
Data are presented as mean 6 SD where applicable. CTA, % indicates percentage of comet tail artifacts in the bright-line lung surface
image; TO, Telazol only; TX, Telazol plus xylazine; and US CTA, US image comet tail artifact width. The intercept for the linear regression
on the means (see Figure 2) approximates the threshold peak rarefactional pressure amplitude for the condition with the corresponding
coefficient of determination (r2). The linear regression intercepts are the apparent thresholds for PCH; regressions were not determined
(ND) for the single data.
aStatistical significance relative to the sham (n 5 6).
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was very low and not significantly different from 0 even
for Telazol plus xylazine. The analysis of variance indi-
cated that both mannitol and albumin infusion with
Telazol plus xylazine gave relatively large pulmonary
diagnostic US-induced PCHs, which were significantly
greater than the result for saline infusion (P< .005 for
mannitol; P< .001 for albumin). Furthermore, the
results for both the on-screen MI of 0.9 (P< .001), and
0.7 (P 5 .015) results were significantly different from
that for the on-screen MI of 0.37 (taken as the sham).
Threshold determination by linear regression pro-
vides an important measure of sensitivity, which uses all
of the data points. For the Telazol-only infusion condi-
tions with only 1 point (on-screen MI of 0.9; Table 3),
the threshold could not be determined by linear regres-
sion but may be assumed to be approximately equal to
the maximum exposure peak rarefactional pressure
amplitude of 2.1 MPa. The data sets for determinations
of thresholds with Telazol plus xylazine were small, as
shown in Figure 2, and the linear regressions had modest
coefficients of determination (r2; Table 3). For the Tela-
zol plus xylazine without infusion and with mannitol and
albumin infusions, the 0 intercepts for linear regression
were all about the same, ranging from peak rarefactional
pressure amplitudes of 1.2 to 1.4 MPa (Table 3). For
Telazol only with no infusion and Telazol plus xylazine
with saline infusion, the 0 crossings were 1.6 to 1.7 MPa,
about 1 exposure step higher than those for the other
conditions.
Discussion
One goal of this study was to compare pulmonary diag-
nostic US-induced PCH results obtained with Telazol-
only and Telazol-plus-xylazine anesthesia as a means to
evaluate enhancement or reduction of the PCH bioeffect
by physiologic conditions. The PCH effect appeared to
be somewhat inhibited relative to previous observations
with this US machine and transducer using ketamine12
rather than Telazol. The on-screen MI of 0.52 yielded
statistically significant PCH for ketamine and xylazine
anesthesia in that study but not in this study with
Telazol-plus-xylazine anesthesia. However, the Telazol-
only condition produced very similar results as ketamine
in a previous study.15 The Telazol mixture provides
much better immobilization than ketamine only and
analgesia sufficient for minor surgical procedures, such
as placement of a jugular vein catheter.
The Telazol-only and Telazol-plus-xylazine compar-
ison was used to test for PCH reduction or enhance-
ment by IV fluid infusion. The main finding in this study
was that infusion tended to reduce PCH. The Telazol-
Figure 1. Pulmonary capillary hemorrhage areas measured on the
lung surface for the on-screen MI 0.9 groups. Asterisks signify means
that are statistically significantly different from the sham. The fraction
above each bar is the positive fraction for the group. The results for
saline infusion were remarkably low for both the Telazol-only and
Telazol-plus-xylazine anesthesia, which was significantly less than the
Telazol-plus-xylazine group with no infusion (P<.001). For Telazol
plus xylazine, the no-infusion (none), mannitol infusion, and albumin
infusion results were all about the same. However, the mannitol and
albumin infusions significantly enhanced the PCH relative to saline
infusion.
Figure 2. Results for the pulmonary capillary hemorrhage areas for
the exposure response tests. TO indicates Telazol-only anesthesia;
and TX, Telazol-plus-xylazine anesthesia. The 0-crossing values of
the linear regressions provide values for the PCH thresholds (see
Table 3). The saline infusion eliminated the enhancement effect of the
xylazine.
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only anesthesia without infusion gave statistically signifi-
cant PCH (P< .02) at an on-screen MI of 0.9, but
Telazol-only conditions with infusion produced no sig-
nificant PCH. An overall comparison of the 5/6 propor-
tion of occurrence for Telazol only without infusion
with the 3/15 occurrence for Telazol only with any
infusion was a significant reduction at P 5 .028. For
Telazol-plus-xylazine anesthesia, saline infusion elimi-
nated the enhancement by xylazine. The mannitol and
albumin infusions had no clear impact on the PCH rela-
tive to the no-infusion part of the study. However,
within the infusion part of the study, the comparison of
saline to albumin infusion was striking: Saline infusion
with Telazol plus xylazine did not give statistically sig-
nificant PCH at the on-screen MI of 0.9. However,
mannitol and albumin infusion resulted in observed
PCH, which was significantly greater (P< .001) than
for saline infusion.
In conclusion, the Telazol-only and Telazol-plus-
xylazine strategy for assessing conditions favoring or
inhibiting pulmonary diagnostic US-induced PCH was
validated, with lower PCH for Telazol only and higher
PCH for Telazol plus xylazine. For infusion, the most
substantial change was the elimination of significant pul-
monary diagnostic US-induced PCH for saline infusion
with Telazol plus xylazine and the reduction to insignifi-
cance of PCH by all the infusions for Telazol-only anes-
thesia. The mechanism for the reduction in the PCH
effect by saline infusion is uncertain. Because it is neutral
with regard to tonicity and subject to redistribution out-
side the vasculature, the rapid infusion of this crystalloid
gave the lowest increase in blood volume. The striking
difference between the results for saline and albumin
infusion (P< .001) probably arose from the different
disposition of crystalloid and colloid infusions. Albumin
and mannitol have a much greater tendency than saline
to remain within the vasculature, increasing plasma vol-
ume and potentially provoking distension and stress, as
well as recruitment, of pulmonary capillaries, which
could increase vulnerability to pulmonary diagnostic US-
induced PCH. Using the Telazol-only and Telazol-plus-
xylazine test strategy, the infusion did not increase PCH
for Telazol only but rather decreased it. For Telazol plus
xylazine, albumin and mannitol had little effect, but
saline reduced pulmonary diagnostic US-induced PCH
to a level even lower that the Telazol-only result. Overall,
the hypothesis that rapid infusion of IV fluids could
serve as a possible stressor for pulmonary capillaries,
which might enhance pulmonary diagnostic US-induced
PCH, was not supported.
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